Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M.

Breast Cancer Res. 2012 May 2;14(3):R70.

2.

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators.

Lancet Oncol. 2011 Jun;12(6):527-39. doi: 10.1016/S1470-2045(11)70094-8. Epub 2011 May 11. Erratum in: Lancet Oncol. 2013 Feb;14(2):e47.

3.

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.

Cancer Res. 2000 Apr 15;60(8):2155-62.

4.

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.

Dobes P, Podhorec J, Coufal O, Jureckova A, Petrakova K, Vojtesek B, Hrstka R.

Oncol Rep. 2014 Oct;32(4):1695-702. doi: 10.3892/or.2014.3346. Epub 2014 Jul 21.

PMID:
25051299
6.

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassøe AM, Thorsen T, Berntsen H, Børresen-Dale AL, Akslen LA, Lønning PE.

Eur J Cancer. 2003 Mar;39(4):438-46.

PMID:
12751373
7.

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C.

J Clin Oncol. 2013 Mar 1;31(7):860-7. doi: 10.1200/JCO.2011.41.0902. Epub 2013 Jan 22.

PMID:
23341518
8.

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ.

J Clin Oncol. 1998 Feb;16(2):470-9.

PMID:
9469330
9.

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.

10.

p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.

Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.

Cancer Sci. 2014 Jan;105(1):81-8. doi: 10.1111/cas.12302. Epub 2013 Nov 22.

11.

Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.

Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X.

Med Oncol. 2012 Jun;29(2):547-53. doi: 10.1007/s12032-011-9964-2. Epub 2011 Apr 29.

PMID:
21528408
12.

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.

Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB, Kahlenberg MS.

Cancer. 2005 Jun 1;103(11):2252-60.

13.

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.

Bayraktar S, Royce M, Stork-Sloots L, de Snoo F, Glück S.

Med Oncol. 2014 Oct;31(10):163. doi: 10.1007/s12032-014-0163-9. Epub 2014 Sep 4.

PMID:
25186065
14.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
15.

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.

Cancer Res. 2001 Mar 15;61(6):2505-12.

16.

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M; BIG 02-98 Collaborative Group.

J Natl Cancer Inst. 2008 Jan 16;100(2):121-33. doi: 10.1093/jnci/djm287. Epub 2008 Jan 8. Erratum in: J Natl Cancer Inst. 2008 Nov 19;100(22):1655.

PMID:
18182617
17.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Ma X, Le Teuff G, Lacas B, Tsao MS, Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L, Filipits M, Pirker R, Jänne PA, Shepherd FA, Brambilla E, Soria JC, Hainaut P; LACE-Bio Collaborative Group.

J Thorac Oncol. 2016 Jun;11(6):850-61. doi: 10.1016/j.jtho.2016.02.002. Epub 2016 Feb 17.

18.

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C.

J Natl Cancer Inst. 2013 Jul 3;105(13):960-7. doi: 10.1093/jnci/djt121. Epub 2013 Jun 5.

19.

p53 as a specific prognostic factor in triple-negative breast cancer.

Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, Kim JS, Jung SS.

Jpn J Clin Oncol. 2009 Apr;39(4):217-24. doi: 10.1093/jjco/hyp007. Epub 2009 Mar 20.

PMID:
19304743
20.

The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.

Liu Y, Yin W, Yan T, Du Y, Shao Z, Lu J.

Curr Med Res Opin. 2013 Nov;29(11):1453-61. doi: 10.1185/03007995.2013.833088. Epub 2013 Sep 11.

PMID:
23927551

Supplemental Content

Support Center